Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited has provided an update on the deployment of funds raised from its June 2015 A-share placement.

The company said the placement generated net proceeds of RMB 814.3 million, of which RMB 669.9 million has been spent on approved projects to date. Interest and financing income from short-term cash management totalled RMB 63.0 million, leaving RMB 49.1 million in the designated bank account as at Jun, 30 2026.

Following shareholder approval at the May 15 2025 annual general meeting, four original investment projects were either ceased or terminated and unused proceeds—together with interest earned—were earmarked for working-capital purposes. By end-June 2026, RMB 158.3 million had been permanently reallocated to bolster day-to-day funding needs.

The board confirmed that all funds have been managed in line with China Securities Regulatory Commission and Shanghai Stock Exchange requirements, with no instances of non-compliance reported.